AstraZeneca Operating Cycle from 2010 to 2026

AZN Stock  USD 93.18  0.04  0.04%   
AstraZeneca PLC Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to drop to 157.55. During the period from 2010 to 2026, AstraZeneca PLC Operating Cycle quarterly data regression pattern had sample variance of  2,200 and median of  235.75. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
212.18
Current Value
157.55
Quarterly Volatility
46.90681732
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.1 B, Interest Expense of 2 B or Total Revenue of 65.3 B, as well as many indicators such as Price To Sales Ratio of 4.19, Dividend Yield of 0.0221 or PTB Ratio of 5.44. AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
  
Build AI portfolio with AstraZeneca Stock
Check out the analysis of AstraZeneca PLC Correlation against competitors.

Latest AstraZeneca PLC's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of AstraZeneca PLC ADR over the last few years. It is AstraZeneca PLC's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AstraZeneca PLC's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Pretty Stable
   Operating Cycle   
       Timeline  

AstraZeneca Operating Cycle Regression Statistics

Arithmetic Mean224.81
Geometric Mean219.59
Coefficient Of Variation20.87
Mean Deviation36.90
Median235.75
Standard Deviation46.91
Sample Variance2,200
Range194
R-Value0.25
Mean Square Error2,197
R-Squared0.06
Significance0.33
Slope2.35
Total Sum of Squares35,204

AstraZeneca Operating Cycle History

2026 157.55
2025 212.18
2024 235.75
2023 254.49
2022 181.6
2021 311.23
2020 262.24

About AstraZeneca PLC Financial Statements

AstraZeneca PLC investors utilize fundamental indicators, such as Operating Cycle, to predict how AstraZeneca Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 212.18  157.55 

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

  0.85GSK GlaxoSmithKline PLC ADR Earnings Call This WeekPairCorr
  0.85JNJ Johnson JohnsonPairCorr
  0.92MRK Merck Company Earnings Call This WeekPairCorr

Moving against AstraZeneca Stock

  0.84JAGX Jaguar Animal HealthPairCorr
  0.7SAVA Cassava SciencesPairCorr
  0.56SNY Sanofi ADR Earnings Call TodayPairCorr
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out the analysis of AstraZeneca PLC Correlation against competitors.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Will Pharmaceuticals sector continue expanding? Could AstraZeneca diversify its offerings? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AstraZeneca PLC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
0.78
Dividend Share
3.13
Earnings Share
3.01
Revenue Per Share
3.1126
Quarterly Revenue Growth
0.12
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that AstraZeneca PLC's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AstraZeneca PLC represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, AstraZeneca PLC's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.